IL151904A0 - THE HIGH BONE MASS GENE OF 11q13.3 - Google Patents

THE HIGH BONE MASS GENE OF 11q13.3

Info

Publication number
IL151904A0
IL151904A0 IL15190400A IL15190400A IL151904A0 IL 151904 A0 IL151904 A0 IL 151904A0 IL 15190400 A IL15190400 A IL 15190400A IL 15190400 A IL15190400 A IL 15190400A IL 151904 A0 IL151904 A0 IL 151904A0
Authority
IL
Israel
Prior art keywords
bone mass
high bone
mass gene
gene
mass
Prior art date
Application number
IL15190400A
Other languages
English (en)
Original Assignee
Genome Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/544,398 external-priority patent/US6770461B1/en
Priority claimed from US09/543,771 external-priority patent/US6780609B1/en
Application filed by Genome Therapeutics Corp filed Critical Genome Therapeutics Corp
Publication of IL151904A0 publication Critical patent/IL151904A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
IL15190400A 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3 IL151904A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/544,398 US6770461B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 11q13.3
US09/543,771 US6780609B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 1.1q13.3
PCT/US2000/016951 WO2001077327A1 (en) 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3

Publications (1)

Publication Number Publication Date
IL151904A0 true IL151904A0 (en) 2003-04-10

Family

ID=27067425

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15190400A IL151904A0 (en) 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3

Country Status (11)

Country Link
EP (1) EP1268775B1 (pt)
JP (1) JP2004515209A (pt)
CN (1) CN1454256A (pt)
AR (1) AR028316A1 (pt)
AU (2) AU5626900A (pt)
BR (1) BR0017197A (pt)
CA (1) CA2402410A1 (pt)
IL (1) IL151904A0 (pt)
MX (1) MXPA02009791A (pt)
NZ (1) NZ521769A (pt)
WO (1) WO2001077327A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244577B2 (en) 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
EP0988379B1 (en) 1997-04-15 2007-04-11 The Wellcome Trust Limited as Trustee to the Wellcome Trust Ldl-receptor
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
CA2419454A1 (en) * 2000-08-18 2002-02-28 Proskelia Regulator gene and system useful for the diagnosis and therapy of osteoporosis
US7416849B2 (en) * 2001-05-11 2008-08-26 Oscient Pharmaceuticals Corporation HBM variants that modulate bone mass and lipid levels
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
AU2002342734B2 (en) * 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions
AU2003292404A1 (en) * 2002-12-13 2004-07-09 Oxagen Limited Genetic susceptibility
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
JPWO2006004066A1 (ja) * 2004-07-02 2008-04-24 株式会社ロコモジェン Ｓ１−５を含有するタンパク質製剤
ES2577289T3 (es) * 2013-09-16 2016-07-14 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Calreticulina mutante para el diagnóstico de malignidades mieloides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012903A1 (en) * 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
EP0988379B1 (en) * 1997-04-15 2007-04-11 The Wellcome Trust Limited as Trustee to the Wellcome Trust Ldl-receptor
BE1011331A6 (fr) * 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
JP2002506873A (ja) * 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
AU4023200A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
WO2001092891A2 (en) * 2000-05-26 2001-12-06 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
CA2419454A1 (en) * 2000-08-18 2002-02-28 Proskelia Regulator gene and system useful for the diagnosis and therapy of osteoporosis

Also Published As

Publication number Publication date
BR0017197A (pt) 2003-01-14
NZ521769A (en) 2004-12-24
AU2000256269B2 (en) 2006-11-02
AU5626900A (en) 2001-10-23
WO2001077327A1 (en) 2001-10-18
CN1454256A (zh) 2003-11-05
EP1268775A1 (en) 2003-01-02
EP1268775B1 (en) 2008-11-19
CA2402410A1 (en) 2001-10-18
AR028316A1 (es) 2003-05-07
MXPA02009791A (es) 2004-09-06
JP2004515209A (ja) 2004-05-27
AU2000256269A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
HK1058749A1 (en) Bone screw.
MXPA03008216A (es) Derivados de 3-fenilo.
AU5626900A (en) The high bone mass gene of 11q13.3
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
MXPA01011743A (es) Arilpirimidinas substituidas 5-.
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
EG23417A (en) Process for the preparation 7 a-methylsteroids.
MXPA03007242A (es) Delta-1-pirrolinas para control de pestes.
IL162223A0 (en) 1,3-Diarylprop-2-en-1-ones, compositions containing same and use thereof
GB2386580B (en) The bricky's mate
Asplund Isproblem i Barduelva
HK1041606A1 (en) Process for the preparation of n,n'-carbonylbislactams.
TJ375B (en) Implant input of the shokirov-jahongirov.
ZA200210029B (en) Compositions and methods for the modification of gene expression.
HRP980497B1 (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
ZA200204398B (en) "An agitating device".
ZA200205681B (en) "Gaming".
ZA200106261B (en) "The rostering of staff".
AU2002324469A1 (en) Substituted-heteroaryl-7-aza(2.2.1)bicycloheptanes for the treatment of disease
GB0114454D0 (en) The ill pill "pic-ur-up-ur-ur"
PL371851A1 (en) 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
GB0115562D0 (en) None given on form 1/77
TW539396U (en) 090220607